Rezolute (RZLT) Competitors $5.08 +0.07 (+1.40%) (As of 09:25 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RZLT vs. KALV, LFVN, XERS, AVEO, HTBX, ARDX, MESO, ANIP, APLT, and ZYMEShould you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include KalVista Pharmaceuticals (KALV), LifeVantage (LFVN), Xeris Biopharma (XERS), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX), Ardelyx (ARDX), Mesoblast (MESO), ANI Pharmaceuticals (ANIP), Applied Therapeutics (APLT), and Zymeworks (ZYME). These companies are all part of the "medical" sector. Rezolute vs. KalVista Pharmaceuticals LifeVantage Xeris Biopharma AVEO Pharmaceuticals Heat Biologics Ardelyx Mesoblast ANI Pharmaceuticals Applied Therapeutics Zymeworks Rezolute (NASDAQ:RZLT) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership. Does the media favor RZLT or KALV? In the previous week, KalVista Pharmaceuticals had 6 more articles in the media than Rezolute. MarketBeat recorded 7 mentions for KalVista Pharmaceuticals and 1 mentions for Rezolute. Rezolute's average media sentiment score of 0.66 beat KalVista Pharmaceuticals' score of 0.32 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KalVista Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer RZLT or KALV? Rezolute presently has a consensus target price of $24.13, indicating a potential upside of 374.90%. KalVista Pharmaceuticals has a consensus target price of $26.00, indicating a potential upside of 190.50%. Given Rezolute's higher probable upside, research analysts clearly believe Rezolute is more favorable than KalVista Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer RZLT or KALV? KalVista Pharmaceuticals received 270 more outperform votes than Rezolute when rated by MarketBeat users. However, 78.82% of users gave Rezolute an outperform vote while only 74.39% of users gave KalVista Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRezoluteOutperform Votes6778.82% Underperform Votes1821.18% KalVista PharmaceuticalsOutperform Votes33774.39% Underperform Votes11625.61% Do insiders and institutionals have more ownership in RZLT or KALV? 83.0% of Rezolute shares are held by institutional investors. 20.8% of Rezolute shares are held by company insiders. Comparatively, 10.5% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has preferable earnings and valuation, RZLT or KALV? Rezolute is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRezoluteN/AN/A-$68.46M-$1.27-4.00KalVista PharmaceuticalsN/AN/A-$126.64M-$3.53-2.54 Which has more volatility and risk, RZLT or KALV? Rezolute has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Is RZLT or KALV more profitable? Rezolute's return on equity of -69.83% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets RezoluteN/A -69.83% -62.16% KalVista Pharmaceuticals N/A -97.37%-82.39% SummaryRezolute beats KalVista Pharmaceuticals on 11 of the 14 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Rezolute News Delivered to You Automatically Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RZLT vs. The Competition Export to ExcelMetricRezolutePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$294.34M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-4.004.8587.8613.46Price / SalesN/A374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book2.5910.216.946.30Net Income-$68.46M$153.61M$119.12M$225.93M7 Day Performance-9.29%-2.00%-1.84%-1.32%1 Month Performance3.89%-7.47%-3.65%0.60%1 Year Performance531.53%31.80%31.64%26.23% Rezolute Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RZLTRezolute4.1532 of 5 stars$5.08+1.4%$24.13+374.9%+568.0%$294.34MN/A-4.0040KALVKalVista Pharmaceuticals3.7142 of 5 stars$8.95-0.1%$26.00+190.5%+9.1%$386.82MN/A0.00150Insider TradeNews CoverageLFVNLifeVantage2.9406 of 5 stars$12.93-4.6%N/A+121.0%$161.88M$200.16M40.41260XERSXeris Biopharma3.9457 of 5 stars$3.01-1.6%$4.87+61.7%+68.1%$448.73M$163.91M0.00290AVEOAVEO PharmaceuticalsN/A$15.00flatN/A+0.0%$521.45M$42.29M-17.86114HTBXHeat BiologicsN/AN/AN/AN/A$61.05MN/A0.0049ARDXArdelyx4.0013 of 5 stars$4.92+2.7%$10.42+111.7%+12.3%$1.17B$124.46M0.00267Short Interest ↑Gap UpMESOMesoblast1.3555 of 5 stars$10.10-2.2%$11.50+13.9%+345.3%$1.15B$5.90M0.0080Gap DownANIPANI Pharmaceuticals4.3361 of 5 stars$54.30-1.5%$77.33+42.4%+7.4%$1.14B$486.82M0.00642Positive NewsAPLTApplied Therapeutics4.3469 of 5 stars$9.75+3.4%$12.50+28.2%+373.9%$1.13B$9.99M0.0030ZYMEZymeworks2.4008 of 5 stars$15.51+6.6%$19.00+22.5%+74.0%$1.07B$76.01M0.00290 Related Companies and Tools Related Companies KALV Alternatives LFVN Alternatives XERS Alternatives AVEO Alternatives HTBX Alternatives ARDX Alternatives MESO Alternatives ANIP Alternatives APLT Alternatives ZYME Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RZLT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
